Using Wearable Technology to Generate Objective Parkinson’s Disease Dyskinesia Severity Score: Possibilities for Home Monitoring

Authors: Delrobaei, Mehdi, Baktash, Navid, Gilmore, Greydon, McIsaac, Kenneth, Jog, Mandar

Source: IEEE transactions on neural systems and rehabilitation engineering. 25(10):1853-1863

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100121551315.0x000001&indx=1&recIds=ETOCvdc_100121551315.0x000001

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.

Authors: Schmid, Peter, Cortes, Javier, Joaquim, Ana, Jañez, Noelia Martínez, Morales, Serafín, Díaz-Redondo, Tamara, Blau, Sibel, Neven, Patrick, Lemieux, Julie, García-Sáenz, José Ángel, Hart, Lowell, Biyukov, Tsvetan, Baktash, Navid, Massey, Dan, Burris III, Howard A., Rugo, Hope S.

Source: Breast Cancer Research; 6/12/2023, Vol. 25 Issue 1, p1-10, 10p

Subject Terms: HORMONE receptor positive breast cancer, METASTATIC breast cancer, EVEROLIMUS, EPIDERMAL growth factor, CANCER patients, CYCLIN-dependent kinase inhibitors

Errata to 'Using Wearable Technology to Generate Objective Parkinson’s Disease Dyskinesia Severity Score: Possibilities for Home Monitoring'

Authors: Delrobaei, Mehdi, Baktash, Navid, Gilmore, Greydon, McIsaac, Kenneth, Jog, Mandar

Source: IEEE transactions on neural systems and rehabilitation engineering. 25(11):2214-2214

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100121551288.0x000001&indx=1&recIds=ETOCvdc_100121551288.0x000001

This result is not displayed to guests.
Login for full access.